Mineralization pattern of the deep gray matter by susceptibility-weighted magnetic resonance imaging to differentiate Parkinsonian disorders
Objective: To study mineralization pattern of the deep gray matter by susceptibility-weighted (SWI) magnetic resonance imaging to differentiate Parkinson’s disease and atypical parkinsonian disorders like…Usefulness of combined examination using Frontal Assessment Battery (FAB) and Single Photon Emission Computer Tomography in the differentiation of 4 repeats (4R) tauopathic atypical parkinsonism
Objective: The aim of the work is to analyze whether combined examination of the frontal lobe using single photon emission computer tomography (SPECT) and Frontal…Analysis of Tau Burden and Distribution on the Spectrum of PSP Subtypes
Objective: The aim of this study was to assess the previous hypothesis about relationship between clinical spectrum of Progressive Supranuclear Palsy (PSP) and tau burden…The difference in cerebellar blood flow reduction in multiple system atrophy and Parkinson’s disease
Objective: The aim of this study is to determine if cerebral blood flow (CBF) reduction in the cerebellum could be a tool for differential diagnosis…Serum fractalkine levels in Parkinson’s disease: Evidence for neuroinflammation
Objective: Parkinson's disease (PD) is a debilitating neurodegenerative disorder characterized by loss of dopamine neurons in the substantia nigra. We measured neuroinflammatory marker fractalkine in…Amyotrophic Lateral Sclerosis-Progressive Supranuclear Palsy Phenotype with Negative C9ORF72 Mutation
Objective: We report a rare case of amyotrophic lateral sclerosis (ALS) / progressive supranuclear palsy (PSP) phenotype. Background: Increasing evidence supports a common pathophysiology between…Salivary Alpha-Synuclein and tau in Parkinson’s Disease and Progressive Supranuclear Palsy
Objective: The aim of this study is to measure alpha-synuclein (a-syn) total, a-syn oligomers (a-syn olig) and total tau protein concentration in the saliva of…Quantitative Midbrain Measurement in Diagnosing Variants of Progressive Supranuclear Palsy
Objective: To evaluate the effectiveness of quantitative midbrain measurements in differentiating vPSP from multiple system atrophy (MSA) and Parkinson’s disease (PD). Background: Newly published criteria…Evolution of diagnostic certainty and PSP-predominance types in 187 pathologically confirmed PSP patients
Objective: To examine the evolution of diagnostic certainty and clinical predominance types as defined by the movement disorder society (MDS) criteria for the clinical diagnosis…ARISE study: Study Design and Baseline Characteristics for a Phase 2 Trial of the Anti-Tau Antibody ABBV-8E12 in Progressive Supranuclear Palsy
Objective: This double-blind, placebo-controlled phase 2 study (M15-562 ARISE study, NCT02985879) assesses the safety and efficacy of ABBV-8E12 treatment in patients with progressive supranuclear palsy…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 33
- Next Page »